KCA
Search
- Page Path
- HOME > Search
Original Articles
- Gastrointestinal cancer
- Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for More Than 1 Year
- Youngun Kim, Jung Sun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Yun Beom Sang, Sanghoon Jung, Chansik An, Chan Kim, Hong Jae Chon
- Cancer Res Treat. 2024;56(4):1231-1239. Published online May 27, 2024
- DOI: https://doi.org/10.4143/crt.2024.237
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Purpose
Since 2020, atezolizumab plus bevacizumab (Ate/Bev) has been the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), but long-term treatment studies are limited. This study evaluated the clinical characteristics and effects of Ate/Bev for over 1 year.
Materials and Methods
This study included patients with unresectable HCC treated with first-line Ate/Bev between May 2020 and April 2022. Those receiving Ate/Bev for 1 year or more were classified as the long-term treatment group.
Results
Of 246 patients, 69 (28.0%) were in the long-term treatment group, which comprised more proportions of intrahepatic tumor burden < 25%, Eastern Cooperative Oncology Group 0, and a lower proportion of portal vein tumor thrombosis than the short-term treatment group. The long-term treatment group had a higher incidence of atezolizumab-related thyroid dysfunction (31.9% vs. 10.7%, p < 0.001; median time to onset [mTTO], 2.8 months), dermatologic toxicity (29.0% vs. 14.7%, p=0.017; mTTO, 3.3 months), bevacizumab-related hypertension (44.9% vs. 22.0%, p=0.001; mTTO, 4.2 months), and proteinuria (69.6% vs. 38.4%, p < 0.001; mTTO, 6.8 months), compared to the short-term treatment group. Regarding liver function in the long-term treatment group, patients initially classified as Child-Pugh class A decreased from 87.0% to 75.4%, and albumin-bilirubin grade 1 decreased from 68.1% to 50.7% after 1 year of treatment.
Conclusion
The Ate/Bev long-term treatment group had a lower intrahepatic tumor burden, less portal vein tumor thrombosis, and better performance status and liver function at baseline. Atezolizumab-related immunological adverse events emerged relatively early in treatment compared to the bevacizumab-related. Additionally, some patients demonstrated liver function deterioration during long-term Ate/Bev treatment.
- 1,694 View
- 136 Download
- ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer
- Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Beodeul Kang, Chan Kim, Hyo Sup Shim, Young Nyun Park, Sanghoon Jung, Sung Hoon Choi, Hye Jin Choi, Choong-kun Lee, Hong Jae Chon
- Cancer Res Treat. 2023;55(4):1291-1302. Published online May 3, 2023
- DOI: https://doi.org/10.4143/crt.2022.1450
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
There are clinical unmet needs in predicting therapeutic response and precise strategy for the patient with advanced biliary tract cancer (BTC). We aimed to identify genomic alterations predicting therapeutic response and resistance to gemcitabine and cisplatin (Gem/Cis)-based chemotherapy in advanced BTC.
Materials and Methods
Genomic analysis of advanced BTC multi-institutional cohorts was performed using targeted panel sequencing. Genomic alterations were analyzed integrating patients’ clinicopathologic data, including clinical outcomes of Gem/Cis-based therapy. Significance of genetic alterations was validated using clinical next-generation sequencing (NGS) cohorts from public repositories and drug sensitivity data from cancer cell lines.
Results
193 BTC patients from three cancer centers were analyzed. Most frequent genomic alterations were TP53 (55.5%), KRAS (22.8%), ARID1A (10.4%) alterations, and ERBB2 amplification (9.8%). Among 177 patients with BTC receiving Gem/Cis-based chemotherapy, ARID1A alteration was the only independent predictive molecular marker of primary resistance showing disease progression for 1st-line chemotherapy in the multivariate regression model (odds ratio, 3.12; p=0.046). In addition, ARID1A alteration was significantly correlated with inferior progression-free survival on Gem/Cis-based chemotherapy in the overall patient population (p=0.033) and in patients with extrahepatic cholangiocarcinoma (CCA) (p=0.041). External validation using public repository NGS revealed that ARID1A mutation was a significant predictor for poor survival in BTC patients. Investigation of multi-OMICs drug sensitivity data from cancer cell lines revealed that cisplatin-resistance was exclusively observed in ARID1A mutant bile duct cancer cells.
Conclusion
Integrative analysis with genomic alterations and clinical outcomes of the first-line Gem/Cis-based chemotherapy in advanced BTC revealed that patients with ARID1Aalterations showed a significant worse clinical outcome, especially in extrahepatic CCA. Well-designed prospective studies are mandatory to validate the predictive role of ARID1Amutation. -
Citations
Citations to this article as recorded by
- ARID1A in Gynecologic Precancers and Cancers
Jaida E. Morgan, Nishah Jaferi, Zainab Shonibare, Gloria S. Huang
Reproductive Sciences.2024; 31(8): 2150. CrossRef - Genomic analysis of bladder urothelial carcinoma with osteoclast‑like giant cells: A case report
Koji Kameyama, Kosuke Mizutani, Tetsuya Yamada, Seiji Sugiyama, Shingo Kamei, Shigeaki Yokoi, Kengo Matsunaga, Koseki Hirade, Yasutaka Kato, Hiroshi Nishihara, Satoshi Ishihara, Takashi Deguchi
Molecular and Clinical Oncology.2024;[Epub] CrossRef - A mutational signature and ARID1A mutation associated with outcome in hepatocellular carcinoma
Wei Zhou, Hao Chi, Xiaohu Zhao, Guangrong Tao, Jianhe Gan
Clinical and Translational Oncology.2024;[Epub] CrossRef - Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer
Sohyun Hwang, Seonjeong Woo, Beodeul Kang, Haeyoun Kang, Jung Sun Kim, Sung Hwan Lee, Chang Il Kwon, Dong Soo Kyung, Hwang-Phill Kim, Gwangil Kim, Chan Kim, Hong Jae Chon
Journal of Hepatology.2024;[Epub] CrossRef - Advances in the study of the role of high-frequency mutant subunits of the SWI/SNF complex in tumors
Jiumei Zhao, Jing Zhu, Yu Tang, Kepu Zheng, Ziwei Li
Frontiers in Oncology.2024;[Epub] CrossRef - The role of ARID1A in malignant neoplasms of the female reproductive system: a modern view on diagnostic and therapeutic opportunities
A. I. Marzaganova, I. R. Martirosyan, A. S. Korchemkina, E. G. Avanesyan, D. A. Korkmazova, O. B. Grakhnova, V. V. Akimina, A. P. Dzhamalutdinova, D. A. Bolloev, A. M. Dugulbgova, Z. G. Bakhmudova, A. T. Salikhova, P. A. Dzigora
Obstetrics, Gynecology and Reproduction.2024;[Epub] CrossRef
- ARID1A in Gynecologic Precancers and Cancers
- 3,956 View
- 333 Download
- 4 Web of Science
- 6 Crossref
Case Report
- An Unusual Presentation of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma as Diffuse Pulmonary Infiltrates with Spontaneous Regression
- Hye Seon Kang, Hea Yon Lee, Seung Joon Kim, Seok Chan Kim, Young Kyoon Kim, Gyeong Sin Park, Kyo Young Lee, Jung Im Jung, Ji Young Kang
- Cancer Res Treat. 2015;47(4):943-948. Published online September 15, 2014
- DOI: https://doi.org/10.4143/crt.2014.016
-
Abstract
PDFPubReaderePub
- A 57-year-old woman presented with cough and dyspnea for 2 months. Computed tomography of the chest showed diffuse ground-glass opacities in both lungs. Histologic examination via thoracoscopic lung biopsy revealed atypical lymphoproliferative lesion. Her symptoms and radiologic findings of the chest improved just after lung biopsy without any treatment. Therefore, she was discharged and monitored at an outpatient clinic. Two months later, pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma was confirmed by the detection of API2-MALT1 translocation in fluorescent in situ hybridization analysis. Although the lung lesions resolved spontaneously, she received chemotherapy due to bone marrow involvement in her staging workup. Pulmonary MALT lymphoma is rare. Nodular or consolidative patterns are the most frequent radiologic findings. Although the disease has an indolent growth, it rarely resolves without treatment. We report an unusual case of pulmonary MALT lymphoma with diffuse interstitial abnormalities on image and spontaneous regression on clinical course.
-
Citations
Citations to this article as recorded by- Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma
Huahang Lin, Ke Zhou, Zhiyu Peng, Linchuan Liang, Jie Cao, Jiandong Mei
Frontiers in Oncology.2022;[Epub] CrossRef - Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography
Michael P. MacManus, Michael S. Hofman, Rodney J. Hicks, Belinda A. Campbell, Andrew Wirth, John F. Seymour, Nicole Haynes, Kate Burbury
International Journal of Radiation Oncology*Biology*Physics.2020; 108(1): 204. CrossRef - Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with Spontaneous Regression after Computed Tomography-guided Needle Biopsy: A Case Report and Summary of 8 Reported Cases
Kazuaki Fukushima, Susumu Hirosako, Yuki Tenjin, Yosuke Mukasa, Keisuke Kojima, Sho Saeki, Shinichiro Okamoto, Hidenori Ichiyasu, Kazuhiko Fujii, Yoshitaka Kikukawa, Koichi Kawanaka, Hirotsugu Kohrogi
Internal Medicine.2016; 55(24): 3655. CrossRef - A Rare Radiological Presentation of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma as Bronchovascular Thickening and Ground Glass Opacities with Concurrent Pancreas Involvement
Yun Mi Kwak, Ho Sung Lee, Ki Hyun Seo, Ji Won Lyu, Si-Hyong Jang, Ju Ock Na
Soonchunhyang Medical Science.2016; 22(2): 151. CrossRef
- Surgery and chemotherapy cannot improve the survival of patients with early-stage mucosa-associated lymphoid tissue derived primary pulmonary lymphoma
- 13,834 View
- 100 Download
- 5 Web of Science
- 4 Crossref
Original Articles
- Predictive Value of In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay in Advanced Gastric Cancer Patients Who Received Oral 5-Fluorouracil after Curative Resection
- Ji Hyun Lee, Min-Chan Kim, Sung Yong Oh, Hyuk-Chan Kwon, Sung-Hyun Kim, Kyung A Kwon, Suee Lee, Jin Sook Jeong, Seok-Reyol Choi, Hyo-Jin Kim
- Cancer Res Treat. 2011;43(2):117-123. Published online June 30, 2011
- DOI: https://doi.org/10.4143/crt.2011.43.2.117
-
Abstract
PDFPubReaderePub
- PURPOSE
To assess the usefulness of adenosine triphosphate-based chemotherapy response assay (ATP-CRA) results in advanced gastric cancer patients receiving adjuvant chemotherapy.
MATERIALS AND METHODS
Sixty-two patients underwent curative surgical resection between January, 2006 and December, 2008. Their highly purified surgical specimens were evaluated by ATP-CRAs. Of the 62, 49 had successful assay results and they received either oral 5-fluorouracil or other chemotherapies. We retrospectively analyzed data for 24 patients who were treated with oral 5-fluorouracil and whose assays were successful.
RESULTS
The median observation time was 24.6 months (range, 10.1 to 40.9 months). The median treatment time was 11.2 months (range, 1.2 to 17.7 months). The median age was 66 years (range, 30 to 81 years). Patients were grouped into sensitive- and resistant-groups according to adenosine triphosphate-based chemotherapy response results for fluorouracil. The sensitive-group showed a significantly longer time to relapse (not reached in the sensitive-group vs. 24.8 months in the resistant-group, p=0.043) and longer overall survival compared to the resistant-group (not reached in the sensitive-group vs. 35.7 months in the resistant-group, p=0.16, statistically insignificant).
CONCLUSION
Patients who receive curative surgical resection significantly benefit from sensitive adjuvant chemotherapy according to ATP-CRA results for time to relapse. -
Citations
Citations to this article as recorded by- In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
Hye Youn Kwon, Im-kyung Kim, Jeonghyun Kang, Seung-Kook Sohn, Kang Young Lee
Cancer Research and Treatment.2016; 48(3): 970. CrossRef - Clinical correlation between <i>in vitro</i> chemoresponse assay and first line chemotherapy for metastatic colorectal cancer patients
Sang Hun Jung, So Hyun Kim, Jae Hwang Kim
Korean Journal of Clinical Oncology.2015; 11(2): 51. CrossRef - Purinergic signalling in the gastrointestinal tract and related organs in health and disease
Geoffrey Burnstock
Purinergic Signalling.2014; 10(1): 3. CrossRef - Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes
KOJI HARADA, TARANNUM FERDOUS, YOSHIYA UEYAMA
International Journal of Oncology.2014; 44(4): 1302. CrossRef - Purinergic signalling and cancer
Geoffrey Burnstock, Francesco Di Virgilio
Purinergic Signalling.2013; 9(4): 491. CrossRef - Establishment and characterization of two 5-fluorouracil-resistant hepatocellular carcinoma cell lines
KAZUYA UCHIBORI, ATSUSHI KASAMATSU, MASAHIKO SUNAGA, SATOSHI YOKOTA, TOMOYA SAKURADA, ERIKO KOBAYASHI, MASAHARU YOSHIKAWA, KATSUHIRO UZAWA, SHIRO UEDA, HIDEKI TANZAWA, NOBUNORI SATO
International Journal of Oncology.2012; 40(4): 1005. CrossRef
- In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer
- 11,444 View
- 46 Download
- 6 Crossref
- Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites
- Joo Hoon Kim, Sun Young Rha, Chan Kim, Gun Min Kim, Sang Hyun Yoon, Ki Hyang Kim, Min Jae Kim, Joong Bae Ahn, Hyun Cheol Chung, Jae Kyung Roh, Hyo Song Kim
- Cancer Res Treat. 2010;42(4):217-224. Published online December 31, 2010
- DOI: https://doi.org/10.4143/crt.2010.42.4.217
-
Abstract
PDFPubReaderePub
Purpose We investigated the clinicopathologic information of patients with gastric cancer with multiple primary cancers (GC-MPC) of three or more sites.
Materials and Methods Between 1995 and 2009, 105,908 patients were diagnosed with malignancy at Severance Hospital, Yonsei University Health System. Of these, 113 (0.1%) patients with MPC of three or more sites were registered, and 41 (36.3%) of these were GC-MPC. We retrospectively reviewed the clinical data and overall survival using the medical records of these 41 GC-MPC patients. We defined synchronous cancers as those occurring within 6 months of the first primary cancer, while metachronous cancers were defined as those occurring more than 6 months later.
Results Patients with metachronous GC-MPC were more likely to be female (p=0.003) and young than patients with synchronous GC-MPC (p=0.013). The most common cancer sites for metachronous GC-MPC patients were the colorectum, thyroid, lung, kidney and breast, while those for synchronous GC-MPC were the head and neck, esophagus, lung, and kidney. Metachronous GC-MPC demonstrated significantly better overall survival than synchronous GC-MPC, with median overall survival durations of 4.7 and 14.8 years, respectively, and 10-year overall survival rates of 48.2% and 80.7%, respectively (p<0.001).
Conclusion Multiplicity of primary malignancies itself does not seem to indicate a poor prognosis. The early detection of additional primary malignancies will enable proper management with curative intent.
-
Citations
Citations to this article as recorded by- Metachronous or Synchronous Presentation of Acute Myeloid Leukemia and Lung Cancer: A Single Center Experience
Başak Ünver Koluman, Atike Gökçen Demiray, Gulsum Akgun Cagliyan, Sibel Hacıoğlu, Nil Güler, Taner Durak, Yeliz Karakaya, Ferda Bir
Akdeniz Medical Journal.2024;[Epub] CrossRef - A Disguising Fast-Growing Metachronous Melanoma and COVID-19
Alina Avram, Lucian G Scurtu, Mariana Costache, Olga Simionescu
Cureus.2023;[Epub] CrossRef - Solitary solutions to a metastasis model represented by two systems of coupled Riccati equations
I. Timofejeva, T. Telksnys, Z. Navickas, R. Marcinkevicius, R. Mickevicius, M. Ragulskis
Journal of King Saud University - Science.2023; 35(5): 102682. CrossRef - Triple synchronous malignancies of the stomach, bladder and thyroid in a previously treated prostate cancer patient: A Case Report
Oliver Oey, Siaw Sze Tiong, Sze Ling Wong, Suresh Navadgi, Yasir Khan
Folia Medica.2023; 65(4): 693. CrossRef - Features of synchronous and metachronous dual primary gastric and colorectal cancer
Yi-Jia Lin, Hua-Xian Chen, Feng-Xiang Zhang, Xian-Sheng Hu, Hai-Juan Huang, Jian-Hua Lu, Ye-Zi Cheng, Jun-Sheng Peng, Lei Lian
World Journal of Gastrointestinal Oncology.2023; 15(11): 1864. CrossRef - Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
Tiuri E. Kroese, Richard van Hillegersberg, Sebastian Schoppmann, Pieter R.A.J. Deseyne, Philippe Nafteux, Radka Obermannova, Marianne Nordsmark, Per Pfeiffer, Maria A. Hawkins, Elizabeth Smyth, Sheraz Markar, George B. Hanna, Edward Cheong, Asif Chaudry,
European Journal of Cancer.2022; 164: 18. CrossRef - Stereotactic radiotherapy or metastasectomy for oligometastatic esophagogastric cancer: A nationwide population-based cohort study
Tiuri E. Kroese, Nikita K.N. Jorritsma, Hanneke W.M. van Laarhoven, Rob H.A. Verhoeven, Stella Mook, Nadia Haj Mohammad, Jelle P. Ruurda, Peter S.N. van Rossum, Richard van Hillegersberg
Clinical and Translational Radiation Oncology.2022; 37: 109. CrossRef - Simultaneous triple primary malignancies, including bladder cancer, lymphoma, and lung cancer, in an elderly male: A case report
Risheng Huang, Zhijia Li, Shanshan Weng, Shenghao Wu
Open Life Sciences.2022; 17(1): 1263. CrossRef - A Case Report of Mesothelioma Response to Endocrine Therapy in Synchronous Breast Cancer and Pleural Epithelioid Mesothelioma: A Double Exemestane Effect
Marta Pina, Rute Fernandes, Diogo Fonseca, Cristina Oliveira, Ana Rodrigues
Cureus.2022;[Epub] CrossRef - Management of patients with synchronous head-and-neck and lung cancers
Nicolas Paleiron, Radj Gervais, Gaelle Rousseau-Bussac, Laurence Bigay Game, Anne Marie Chiappa, Regine Lamy, Florian Guisier, Hervé Le Caer, Gilles Robinet, Acya Bizieux, Christos Chouaïd
Journal of Cancer Research and Therapeutics.2022; 18(Suppl 2): S160. CrossRef - Multiple primary malignancies involving lung cancer: a single-center experience
Luigi Ventura, Paolo Carbognani, Letizia Gnetti, Maurizio Rossi, Marcello Tiseo, Enrico Maria Silini, Nicola Sverzellati, Mario Silva, Marcello Succi, Cesare Braggio, Sara Cattadori, Giovanni Bocchialini, Valeria Balestra, Michele Rusca, Luca Ampollini
Tumori Journal.2021; 107(3): 196. CrossRef - A Case Series of Multiple Primary Malignancies Among Patients With Advanced Melanoma
Matthew I Ebia, Stephen Capone, Charité Ricker, Jacob S Thomas, Varsha Tulpule, Irene Kang, Anishka D'Souza, David R Freyer, Kimberly Miller, Gino K In
Cureus.2021;[Epub] CrossRef - A Rare Case of Synchronous Esophageal and Pancreatic Malignancy
Ali Khalifa, Arkady Broder
Cureus.2021;[Epub] CrossRef - Efficacy and Safety of Local Radiotherapy to All Oligometastatic Sites in Elderly Patients with Metachronous Oligometastatic Cancers After Initial Treatment for the Primary Tumor
Xiaolong Hu, Hongqi Li, Xiaoli Kang, Xuan Wang, Haifeng Pang, Chen Liu, Jianchun Zhang, Yingjie Wang
Cancer Management and Research.2021; Volume 13: 9247. CrossRef - Synergistic Effect of Lymphatic Invasion and Venous Invasion on the Risk of Lymph Node Metastasis in Patients with Non-Curative Endoscopic Resection of Early Gastric Cancer
Hye Jin Kang, Hyunsoo Chung, Sang Gyun Kim, Jung Kim, Jue Lie Kim, Eunwoo Lee, Hyun Chae Jung
Journal of Gastrointestinal Surgery.2020; 24(7): 1499. CrossRef - Clear cell renal carcinoma synchronous with dedifferentiated liposarcoma: a case report and review of the literature
Estefania Beltran, Juan Esteban Garcia-Robledo, Lisa X. Rodríguez-Rojas, Martin Rengifo, Bladimir Perez, Harry Pachajoa, Angela R. Zambrano
Journal of Medical Case Reports.2020;[Epub] CrossRef - Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
Matthias Guckenberger, Yolande Lievens, Angelique B Bouma, Laurence Collette, Andre Dekker, Nandita M deSouza, Anne-Marie C Dingemans, Beatrice Fournier, Coen Hurkmans, Frédéric E Lecouvet, Icro Meattini, Alejandra Méndez Romero, Umberto Ricardi, Nicola S
The Lancet Oncology.2020; 21(1): e18. CrossRef - Rare heterochronous liver and pancreatic multiple primary cancers: a case report and literature review
Wangjun Zhang, Fan Xiao, Jie Li, Xiaoyu Guo, Zhitao Lin, Zijian Huang, Ning Mao, Bei Sun, Gang Wang
Zeitschrift für Gastroenterologie.2020; 58(11): 1094. CrossRef - Gastric carcinoma and renal cell carcinoma as an atypical presentation of multiple primary malignancies: a case report and review of the literature
J. A. Martín-Pérez, C. Torres-Silva, R. Tenorio-Arguelles, D. A. García-Corona, S. Silva-González, J. A. Dominguez-Rodriguez, I. De Alba-Cruz, J. F. Nagore-Ancona, J. A. González-Luna, K. A. López-Bochm
Journal of Medical Case Reports.2020;[Epub] CrossRef - Helicobacter pylori Eradication for Metachronous Gastric Cancer: An Unsuitable Methodology Impeding Broader Clinical Usage
Alexios-Fotios A. Mentis, Efthimios Dardiotis
Frontiers in Oncology.2019;[Epub] CrossRef - A case report of cholangiocarcinoma combined with moderately differentiated gastric adenocarcinoma
Yan-Hui Yang, Qing Deng, Tian-Bao Yang, Yang Gui, Yu-xiang Zhang, Jiang-Bo Liu, Qian Deng, Wei-Feng Liu, Jun-Jun Sun
Medicine.2019; 98(30): e16332. CrossRef - Management and Follow-up of Patients with a Bronchial Neuroendocrine Tumor in the Last Twenty Years in Ireland: Expected Inconsistencies and Unexpected Discoveries
Asta Agasarova, Clare Harnett, Niall Mulligan, Muhammad Shakeel Majeed, Alberto Caimo, Gianluca Tamagno
International Journal of Endocrinology.2018; 2018: 1. CrossRef - Clinicopathologic characteristics and survival rate in patients with synchronous or metachronous double primary colorectal and gastric cancer
Ji-Hyeon Park, Jeong-Heum Baek, Jun-Young Yang, Won-Suk Lee, Woon-Kee Lee
Korean Journal of Clinical Oncology.2018; 14(2): 83. CrossRef - Synchronous primary of periampullary and lung cancer: A case report and review of literature
Vikas Talreja, Vanita Noronha, Amit Joshi, Vijay Patil, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2018; 1(2): 173. CrossRef - Synchronous occurrence of hereditary gastric adenocarcinoma, gastrointestinal stromal tumor, and esophageal small cell and squamous carcinoma in situ: an extremely rare case report
Huijie Fan, Pei Lu, Li Xu, Yanru Qin, Jing Li
BMC Cancer.2017;[Epub] CrossRef - Multiple primary malignancies involving lung cancer
Feng Li, Wen-Zhao Zhong, Fei-Yu Niu, Ning Zhao, Jin-Ji Yang, Hong-Hong Yan, Yi-Long Wu
BMC Cancer.2015;[Epub] CrossRef - Limitations of PET and PET/CT in detecting upper gastrointestinal synchronous cancer in patients with head and neck carcinoma
Kenichiro Yabuki, Akira Kubota, Choichi Horiuchi, Takahide Taguchi, Goshi Nishimura, Masahiko Inamori
European Archives of Oto-Rhino-Laryngology.2013; 270(2): 727. CrossRef
- Metachronous or Synchronous Presentation of Acute Myeloid Leukemia and Lung Cancer: A Single Center Experience
- 12,303 View
- 98 Download
- 27 Crossref
Case Report
- A Case of 5-Fluorouracil Induced Encephalopathy
- Kyung A Kwon, Hyuk-Chan Kwon, Min Chan Kim, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hyo-Jin Kim
- Cancer Res Treat. 2010;42(2):118-120. Published online June 30, 2010
- DOI: https://doi.org/10.4143/crt.2010.42.2.118
-
Abstract
PDFPubReaderePub
Patients with reduced dihydropyrimidine dehydrogenase (DPD) activity are at risk for experiencing serious adverse effects following 5-fluorouracil (5-FU) based chemotherapy. Neurotoxicity is considered an extremely rare side effect of 5-FU. We report here on an unusual case of 5-FU induced encephalopathy. A 38-year-old woman with advanced gastric carcinoma was treated with adjuvant chemotherapy that consisted of infused 5-FU (1,000 mg/m2) for 5 days and cisplatin (60 mg/m2) on day 1 following total gastrectomy. Nineteen days after starting chemotherapy, the patient displayed a sudden onset of slurred speech, confusion, cognitive disturbances and paranoia. A magnetic resonance image (MRI) of the brain showed no structural abnormalities, and the other laboratory tests provided no explanations for her symptoms, other than a slightly elevated ammonia level. The patient was treated with a lactulose retention enema and thiamine infusion, the 5-FU was halted and her symptoms then recovered after 7 days.
-
Citations
Citations to this article as recorded by- Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
Ana Dias-Carvalho, Mariana Ferreira, Rita Ferreira, Maria de Lourdes Bastos, Susana Isabel Sá, João Paulo Capela, Félix Carvalho, Vera Marisa Costa
Archives of Toxicology.2022; 96(1): 11. CrossRef - Chemotherapy-Induced Acute Reversible Toxic Leukoencephalopathy
A. K. Vishnu, Thara Pratap, Dhanya Jacob, Muhammed Jasim Abdul Jalal, Anupama Gopalakrishnabhakthan
Current Medical Issues.2022; 20(3): 194. CrossRef - Hyperammonemic encephalopathy associated with 5-fluorouracil in a patient with previous orthotopic liver transplantation
Hemnishil K. Marella, Rahul Peravali, Amit L. Jain, Satheesh Nair, Benedict Maliakkal, Uchenna Agbim, Rajanshu Verma
Baylor University Medical Center Proceedings.2020; 33(2): 256. CrossRef - Neurotoxicity of antineoplastic drugs: Mechanisms, susceptibility, and neuroprotective strategies
Claudia Pellacani, Georgios Eleftheriou
Advances in Medical Sciences.2020; 65(2): 265. CrossRef - Thiamine deficiency in the outpatient psychiatric oncology setting: A case series
Rose Zhang, Sudhakar Tummala, Deepti Chopra
Palliative and Supportive Care.2020; 18(5): 609. CrossRef - 5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy
Alice Boilève, Camille Wicker, Benjamin Verret, Florence Leroy, David Malka, Mathieu Jozwiak, Clément Pontoizeau, Chris Ottolenghi, Pascale De Lonlay, Michel Ducreux, Antoine Hollebecque
Anti-Cancer Drugs.2019; 30(3): 313. CrossRef - An imaging-based review of systemic therapies and associated toxicities in metastatic pancreatic cancer as per the 2018 ASCO guidelines: what every radiologist should know
Daniel A. Smith, Bhanusupriya Somarouthu, Nikhil H. Ramaiya
Abdominal Radiology.2019; 44(6): 2182. CrossRef - A case of acute leukoencephalopathy induced by a combination of 5-fluorouracil and metronidazole
Tatsuya Fukumoto, Fumiaki Katada, Susumu Sato, Hidehiro Shibayama, Shigeo Murayama, Toshio Fukutake
Rinsho Shinkeigaku.2018; 58(2): 118. CrossRef - The successful treatment of 5-fluorouracil (5-FU) overdose in a patient with malignancy and HIV/AIDS with uridine triacetate
Cynthia Santos, Brent W. Morgan, Robert J. Geller
The American Journal of Emergency Medicine.2017; 35(5): 802.e7. CrossRef - Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach
Michele Boisdron-Celle, Olivier Capitain, Roger Faroux, Christophe Borg, Jean Philippe Metges, Marie Pierre Galais, Mehdi Kaassis, Jaafar Bennouna, Karine Bouhier-Leporrier, Eric Francois, Isabelle Baumgaertner, Véronique Guerin-Meyer, Oana Cojocarasu, Ce
Seminars in Oncology.2017; 44(1): 13. CrossRef - Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy
Seiichiro Mitani, Shigenori Kadowaki, Azusa Komori, Keiji Sugiyama, Yukiya Narita, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Yozo Sato, Hidekazu Yamaura, Yoshitaka Inaba, Makoto Ishihara, Tsutomu Tanaka, Masahiro Tajika, Kei Muro
Medicine.2017; 96(22): e6874. CrossRef - Chemotherapy induced stroke mimic: 5-Fluorouracil encephalopathy fulfilling criteria for tissue plasminogen activator therapy
May Thuy Nguyen, Robyn Stoianovici, Luigi Brunetti
The American Journal of Emergency Medicine.2017; 35(9): 1389. CrossRef - Cancer screening and treatment in patients with end-stage renal disease: remaining issues in the field of onco-nephrology
Yuichiro Kitai, Takeshi Matsubara, Taro Funakoshi, Takahiro Horimatsu, Manabu Muto, Motoko Yanagita
Renal Replacement Therapy.2016;[Epub] CrossRef - Reversible slurred speech related to capecitabine and lapatinib combination in patients with breast cancer
Hasan Mutlu, Abdullah Büyükçelik, Zeki Akça, Abdülsamet Erden
Journal of Oncology Pharmacy Practice.2015; 21(1): 72. CrossRef - Subacute reversible toxic encephalopathy related to treatment with capecitabine: A case report with literature review and discussion of pathophysiology
E. Lyros, S. Walter, I. Keller, P. Papanagiotou, K. Fassbender
NeuroToxicology.2014; 42: 8. CrossRef - Epilepsy in women with gynecologic malignancies
Yixue Gu, Qin Yang, Xuefeng Wang
Expert Review of Neurotherapeutics.2014; 14(5): 503. CrossRef - Posterior Reversible Encephalopathy Syndrome (PRES) After Treatment With Oxaliplatin and 5-Fluorouracil
Nicholas Truman, Daniel Nethercott
Clinical Colorectal Cancer.2013; 12(1): 70. CrossRef - 5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases
Pierre-Yves Cordier, André Nau, Joseph Ciccolini, Manuela Oliver, Cédric Mercier, Bruno Lacarelle, Eric Peytel
Cancer Chemotherapy and Pharmacology.2011; 68(3): 823. CrossRef
- Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events
- 11,318 View
- 97 Download
- 18 Crossref
Original Articles
- Docetaxel versus Paclitaxel Combined with 5-FU and Leucovorin in Advanced Gastric Cancer: Combined Analysis of Two Phase II Trials
- Hong Jae Chon, Sun Young Rha, Chong Kun Im, Chan Kim, Min Hee Hong, Hye Ryun Kim, Jung Ryun An, Sung Hoon Noh, Hyun Cheol Chung, Hei-Cheul Jeung
- Cancer Res Treat. 2009;41(4):196-204. Published online December 31, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.4.196
-
Abstract
PDFPubReaderePub
Purpose This is an
ad hoc analysis of two phase II studies which compared the efficacy and safety of two taxanes (paclitaxel and docetaxel) combined with 5-fluorouracil (5-FU) and leucovorin (LV) in advanced gastric cancer.Materials and Methods Patients with advanced gastric adenocarcinoma who were untreated or had only received first-line chemotherapy, were treated with either paclitaxel (PFL; 175 mg/m2) or docetaxel (DFL; 75 mg/m2) on day 1, followed by a bolus of LV (20 mg/m2 days 1~3) and a 24-hour infusion of 5-FU (1,000 mg/m2 days 1~3) every 3 weeks. The primary endpoint was overall response rate (ORR) and the secondary endpoint included survival and toxicity.
Results Sixty-six patients received DFL (first-line [n=38]; and second-line [n=28]) and 60 patients received PFL (first-line [n=37]; and second-line [n=23]). The ORRs were not significantly different between the 2 groups (DFL, 26%; PFL, 38%). With a median follow-up of 9.5 months, the progression free survival was 5.2 months (95% confidence interval [CI], 4.2~6.5 months) for DFL and 3.3 months (95% CI, 1.3~5.5 months) for PFL (p=0.17). The overall survival was also comparable between the patients who received DFL and PFL (10.0 months [95% CI, 7.2~12.5 months] and 13.9 months [95% CI, 10.9~19.2 months], respectively; p=0.37). The most frequent grade 3~4 adverse event was neutropenia (DFL, 71%; PFL, 62%). DFL and PFL had different non-hematologic toxicities; specifically, grade ≥3 mucositis (5%) and diarrhea (3%) were common in DFL, while nausea/vomiting (15%) and peripheral neuropathy (5%) were common in PFL.
Conclusion Thus, the two taxanes had similar efficacy in the treatment of advanced gastric cancer, but different toxicity profiles. Prospective comparative studies are required to further clarify the role of taxanes in the treatment of advanced gastric cancer.
-
Citations
Citations to this article as recorded by- Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Diala Merheb, Georgette Dib, Maroun Bou Zerdan, Clara El Nakib, Saada Alame, Hazem I. Assi
Current Cancer Drug Targets.2022; 22(1): 49. CrossRef - Treatment Outcome and Safety of the TCX Regimen for Advanced Gastric Cancer: A Prospective Cohort Study
Hieu Trong Nguyen, Kien Hung Do, Nguyen Ba Le, Thang Tran
Cancer Management and Research.2022; Volume 14: 2825. CrossRef - Role for Drug Transporters in Chemotherapy‐Induced Peripheral Neuropathy
Tore B. Stage, Shuiying Hu, Alex Sparreboom, Deanna L. Kroetz
Clinical and Translational Science.2021; 14(2): 460. CrossRef - Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease
Daniel V.T. Catenacci, Stephanie Moya, Samantha Lomnicki, Leah M. Chase, Bryan F. Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, D. Kyle Hogarth, Oliver S. Eng, Kiran Turaga, Kevin Roggin, Mitchell C.
Cancer Discovery.2021; 11(2): 308. CrossRef - Neuroinflammatory Process Involved in Different Preclinical Models of Chemotherapy-Induced Peripheral Neuropathy
Giulia Fumagalli, Laura Monza, Guido Cavaletti, Roberta Rigolio, Cristina Meregalli
Frontiers in Immunology.2021;[Epub] CrossRef - Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems
Nathan P. Staff, Jill C. Fehrenbacher, Martial Caillaud, M. Imad Damaj, Rosalind A. Segal, Sandra Rieger
Experimental Neurology.2020; 324: 113121. CrossRef - Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma
Yoko Tomita, Max Moldovan, Rachael Chang Lee, Amy HC Hsieh, Amanda Townsend, Timothy Price
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef - Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer
Wan-Cai Que, Yan-Fang Huang, Xiao-Yan Lin, Yan-Qin Lan, Xin-Yan Gao, Xin-Li Wang, Ri-Ping Wu, Bin Du, Xiao-Bin Huang, Hong-qiang Qiu, Dong-Ta Zhong
Anti-Cancer Drugs.2019; 30(3): 302. CrossRef - Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer
Chan Kim, Hong Jae Chon, Joo Hoon Kim, Minkyu Jung, Chung Mo Nam, Hyo Song Kim, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
European Journal of Cancer.2019; 112: 20. CrossRef - Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara, Gail D Lewis Phillips, Tina van der Horst, Marie-Laurence Harle-Yge, Betsy L Althaus, Yoon-K
The Lancet Oncology.2017; 18(5): 640. CrossRef - Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy
Hana Starobova, Irina Vetter
Frontiers in Molecular Neuroscience.2017;[Epub] CrossRef - Identifying therapeutic targets in gastric cancer: the current status and future direction
Beiqin Yu, Jingwu Xie
Acta Biochimica et Biophysica Sinica.2016; 48(1): 90. CrossRef - Role of Transient Receptor Potential Channels in Paclitaxel- and Oxaliplatin-induced Peripheral Neuropathy
Kyoji Taguchi
YAKUGAKU ZASSHI.2016; 136(2): 287. CrossRef - Paclitaxel combined with oxaliplatin as first-line chemotherapy for locally advanced or metastatic gastric cancer
Chunmei Shi, Qiang Chen, Songfei Shen, Riping Wu, Baoyu Yang, Qing Liu, Qian Xu
Expert Review of Anticancer Therapy.2015; 15(5): 595. CrossRef - Corosolic acid enhances 5-fluorouracil-induced apoptosis against SNU-620 human gastric carcinoma cells by inhibition of mammalian target of rapamycin
HYUN SU LEE, JUN BEOM PARK, MYUNG SUN LEE, EUN YOUNG CHA, JI YEON KIM, JI YOUNG SUL
Molecular Medicine Reports.2015; 12(3): 4782. CrossRef - Paclitaxel-based regimens as first-line treatment in advanced gastric cancer
Zengqing Guo, Xiaojie Wang, Rongbo Lin, Ling Chen, Nanfeng Fan, Yu Chen, Jinyuan Lin, Jiami Yu
Journal of Chemotherapy.2015; 27(2): 94. CrossRef - A phase 2 study of fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as a salvage treatment in patients with refractory or relapsed advanced gastric cancer
Rongbo Lin, Nanfeng Fan, Guangfeng Wu, Ying Chen, Zengqing Guo, Xiaojie Wang, Feng Jin, Ling Chen, Jie Liu
Journal of Chemotherapy.2015; 27(1): 52. CrossRef - Paclitaxel combined with capecitabine as first-line chemotherapy for advanced or recurrent gastric cancer
MEIQIN YUAN, YUNSHAN YANG, WANGXIA LV, ZHENGBO SONG, HAIJUN ZHONG
Oncology Letters.2014; 8(1): 351. CrossRef - Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
Andreas A. Argyriou, Jordi Bruna, Paola Marmiroli, Guido Cavaletti
Critical Reviews in Oncology/Hematology.2012; 82(1): 51. CrossRef - Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention
W. Grisold, G. Cavaletti, A. J. Windebank
Neuro-Oncology.2012; 14(suppl 4): iv45. CrossRef - Successful Treatment of a Patient with HER2-Positive Metastatic Gastric Cancer with Third-Line Combination Therapy with Irinotecan, 5-Fluorouracil, Leucovorin and Trastuzumab (FOLFIRI-T)
Florian Weissinger, Marc Reymond, Klaus Dumke, Martin Krüger
Onkologie.2011; 34(10): 548. CrossRef - RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase
Kyung-Hun Lee, Hyung-Seok Hur, Seock-Ah Im, Juhee Lee, Hwang-Phill Kim, Young-Kwang Yoon, Sae-Won Han, Sang-Hyun Song, Do-Youn Oh, Tae-You Kim, Yung-Jue Bang
Cancer Letters.2010; 299(1): 22. CrossRef
- Drug-Induced Peripheral Neuropathy: Diagnosis and Management
- 12,140 View
- 76 Download
- 22 Crossref
- Clinical Value of Ezrin Expression in Primary Osteosarcoma
- Chan Kim, Eunah Shin, Soojung Hong, Hong Jae Chon, Hye Ryun Kim, Jung Ryun Ahn, Min Hee Hong, Woo Ick Yang, Jae Kyung Roh, Sun Young Rha
- Cancer Res Treat. 2009;41(3):138-144. Published online September 28, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.3.138
-
Abstract
PDFPubReaderePub
Purpose Ezrin is a membrane cytoskeletal linker protein and it is known to be associated with metastasis of primary osteosarcoma. The aim of this study is to determine the relationship between an ezrin expression and several key clinical parameters and to elucidate its potential prognostic value for patients with osteosarcoma.
Materials and Methods Seventy patients with histologically confirmed osteosarcoma and who had no distant metastasis were enrolled between 1995 and 2005 at Yonsei Cancer Center, Severance Hospital, Korea. The clinical parameters were retrospectively reviewed and immunohistochemical staining (IHC) for ezrin was performed using the surgically resected specimens.
Results Of the 70 tumor specimens, 39 (55.7%) revealed an ezrin expression. More of an osteoblastic histology and an elevated initial ALP level were observed in the ezrin positive patients than in the ezrin negative patients (p=0.008 and 0.001, respectively). The proportion of patients who favorably responded to neoadjuvant chemotherapy (≥90% necrosis) was significantly higher in the group of ezrin positive patients than that in the group of ezrin negative patient (72.2% vs 45.2%, respectively, p=0.024). The ezrin positive patients showed more frequent recurrence than did the ezrin negative patients (64.1% vs 35.5%, respectively, p=0.017). The patients with an ezrin expression also demonstrated poorer survival than did those patients without ezrin expression (5-year EFS: 31.7% vs 61.3%, respectively, p=0.023, 5-year OS: 53.4% vs 71.0%, respectively, p=0.022). When comparing EFS according to both an ezrin expression and chemoresponsiveness, there were trends that the ezrin negative/chemoresponsive group showed the best 5-year EFS (71.4%), followed by the ezrin negative/chemoresistant group (52.9%), the ezrin positive/chemoresponsive group (38.1%) and the ezrin positive/chemoresistant group (13.6%). These trends were statistically significant (p=0.036).
Conclusion The expression of ezrin by IHC staining was found in 55.7% of the patients with metastasis-free osteosarcoma. Immunoreactivity to ezrin is a negative prognostic factor for survival for the patients suffering with osteosarcoma. Identifying an ezrin expression might offer a valuable piece of information when treating patients with primary osteosarcoma.
-
Citations
Citations to this article as recorded by- Osteosarcoma-Specific Genes as a Diagnostic Tool and Clinical Predictor of Tumor Progression
Pattaralawan Sittiju, Parunya Chaiyawat, Dumnoensun Pruksakorn, Jeerawan Klangjorhor, Weerinrada Wongrin, Phichayut Phinyo, Rawikant Kamolphiwong, Areerak Phanphaisarn, Pimpisa Teeyakasem, Prachya Kongtawelert, Peraphan Pothacharoen
Biology.2022; 11(5): 698. CrossRef - Ezrin gone rogue in cancer progression and metastasis: An enticing therapeutic target
Ganesh Kumar Barik, Osheen Sahay, Debasish Paul, Manas Kumar Santra
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2022; 1877(4): 188753. CrossRef - Mass Spectrometric-Based Proteomics for Biomarker Discovery in Osteosarcoma: Current Status and Future Direction
Nutnicha Sirikaew, Dumnoensun Pruksakorn, Parunya Chaiyawat, Somchai Chutipongtanate
International Journal of Molecular Sciences.2022; 23(17): 9741. CrossRef - Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib
Bulent Cetin, Ipek Isik Gonul, Ozge Gumusay, Baris Afsar, Irem Bilgetekin, Ahmet Ozet, Aytug Uner
Journal of Cancer Research and Therapeutics.2021; 17(2): 408. CrossRef - High expression of EZR (ezrin) gene is correlated with the poor overall survival of breast cancer patients
Rongju Zhang, Shaohui Zhang, Rongge Xing, Qin Zhang
Thoracic Cancer.2019; 10(10): 1953. CrossRef - The clinical prognostic significance of ezrin in patients with bone and soft tissue sarcomas: a meta‐analysis
Feng Wang, Tao Yu, Chengbin Ma, Haifei Zhang, Zhiyu Zhang
FEBS Open Bio.2019; 9(10): 1744. CrossRef - Re-calculating! Navigating through the osteosarcoma treatment roadblock
J. McGuire, T.J. Utset-Ward, D.R. Reed, C.C. Lynch
Pharmacological Research.2017; 117: 54. CrossRef - Correlation of Ezrin Expression Pattern and Clinical Outcomes in Ewing Sarcoma
Thomas Cash, Hong Yin, Courtney McCracken, Zhi Geng, Steven G. DuBois, Bahig M. Shehata, Thomas A. Olson, Howard M. Katzenstein, Cynthia Wetmore
Sarcoma.2017; 2017: 1. CrossRef - Differentially activated Src kinase in chemo‐naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor
Marcella Laschi, Giulia Bernardini, Michela Geminiani, Fabrizio Manetti, Mattia Mori, Adriano Spreafico, Domenico Campanacci, Rodolfo Capanna, Silvia Schenone, Maurizio Botta, Annalisa Santucci
BioFactors.2017; 43(6): 801. CrossRef - The Prognostic Role of Ezrin and HER2/neu Expression in Osteosarcoma
Asmaa G. Abdou, Mona Kandil, Nancy Y. Asaad, Marwa M. Dawoud, Ahmed A. Shahin, Amal F. Abd Eldayem
Applied Immunohistochemistry & Molecular Morphology.2016; 24(5): 355. CrossRef - Establishment of Four New Human Primary Cell Cultures from Chemo‐Naïve Italian Osteosarcoma Patients
Marcella Laschi, Giulia Bernardini, Michela Geminiani, Lorenzo Ghezzi, Loredana Amato, Daniela Braconi, Lia Millucci, Bruno Frediani, Adriano Spreafico, Alessandro Franchi, Domenico Campanacci, Rodolfo Capanna, Annalisa Santucci
Journal of Cellular Physiology.2015; 230(11): 2718. CrossRef - Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data
Hai-Yong Ren, Ling-Ling Sun, Heng-Yuan Li, Zhao-Ming Ye
BioMed Research International.2015; 2015: 1. CrossRef - Prognostic Value of Ezrin in Various Cancers: A Systematic Review and Updated Meta-analysis
Jianwei Li, Kuanhai Wei, Hailang Yu, Dan Jin, Gang Wang, Bin Yu
Scientific Reports.2015;[Epub] CrossRef - Alteration of WWOX in human cancer, a clinical view
Izabela Baryła, Ewa Styczeń-Binkowska, Andrzej K Bednarek
Experimental Biology and Medicine.2015; 240(3): 305. CrossRef - The prognostic value of elevated ezrin in patients with osteosarcoma
Deng-Xing Lun, Yong-Cheng Hu, Zhao-Wan Xu, Li-Na Xu, Bin-Wu Wang
Tumor Biology.2014; 35(2): 1263. CrossRef - Prognostic role of cytovillin expression in patients with osteosarcoma: a meta-analysis
Shibing Guo, Rui Bai, Wei Zhao, Yuxin Wang, Zhenqun Zhao, Wei Feng
Tumor Biology.2014; 35(1): 469. CrossRef - CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity
C Zucchini, M C Manara, R S Pinca, P De Sanctis, C Guerzoni, M Sciandra, P-L Lollini, G Cenacchi, P Picci, L Valvassori, K Scotlandi
Oncogene.2014; 33(15): 1912. CrossRef - Correlations of Ezrin Expression with Pathological Characteristics and Prognosis of Osteosarcoma: A Meta-Analysis
Da-Hang Zhao, Jiang Zhu, Wen-Bo Wang, Feng Dong, Qiao Zhang, Hong-Wu Fan, Jing-Zhe Zhang, Yong-Ming Wang
The Scientific World Journal.2014; 2014: 1. CrossRef - Expression of HMGA1 and Ezrin in laryngeal squamous cell carcinoma
De-Sheng Wang, Chun-Chen Pan, Hai-Chun Lai, Jian-Min Huang
Acta Oto-Laryngologica.2013; 133(6): 626. CrossRef - The β5/focal adhesion kinase/glycogen synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy
Sophie Le Guellec, Elizabeth Cohen-Jonathan Moyal, Thomas Filleron, Marie-Bernadette Delisle, Christine Chevreau, Hervé Rubie, Marie-Pierre Castex, Jerome Sales de Gauzy, Paul Bonnevialle, Anne Gomez-Brouchet
Human Pathology.2013; 44(10): 2149. CrossRef - Meta-analysis of Associations of the Ezrin Gene with Human Osteosarcoma Response to Chemotherapy and Prognosis
Zhe Wang, Mao-Lin He, Jin-Min Zhao, Hai-Hui Qing, Yang Wu
Asian Pacific Journal of Cancer Prevention.2013; 14(5): 2753. CrossRef - The Prognostic Role of Ezrin Immunoexpression in Osteosarcoma: A Meta-Analysis of Published Data
Hongtao Li, Daliu Min, Hui Zhao, Zhiyu Wang, Weixiang Qi, Shuier Zheng, Lina Tang, Aina He, Yuanjue Sun, Yang Yao, Zan Shen, David Loeb
PLoS ONE.2013; 8(6): e64513. CrossRef - Effects of siRNA-mediated Cdc2 silencing on MG63 cell proliferation and apoptosis
XIANG-YONG QUE, YI LI, YU HAN, XIN-ZHI LI
Molecular Medicine Reports.2013; 7(2): 466. CrossRef - Clinicopathologic Implication of Ezrin Expression in Non-small Cell Lung Cancer
Ho Won Lee, Eui Han Kim, Mee-Hye Oh
Korean Journal of Pathology.2012; 46(5): 470. CrossRef - Effects of transplantation sites on tumour growth, pulmonary metastasis and ezrin expression of canine osteosarcoma cell lines in nude mice
T. Jaroensong, Y. Endo, S.‐J. Lee, A. Kamida, M. Mochizuki, R. Nishimura, N. Sasaki, T. Nakagawa
Veterinary and Comparative Oncology.2012; 10(4): 274. CrossRef - Prognostic implication of ezrin expression in esophageal squamous cell carcinoma
Jian‐Jun Xie, Li‐Yan Xu, Zhi‐Yong Wu, Qing Zhao, Xiu‐E Xu, Jian‐Yi Wu, Qiao Huang, En‐Min Li
Journal of Surgical Oncology.2011; 104(5): 538. CrossRef - Identification of the VIL2 enhancer in human embryonic kidney cells
Shu‐Ying Gao, Yan‐Peng Dai, Xia Long, Fang‐Ting Zhang, Jie Yu
Cell Biology International.2011; 35(10): 967. CrossRef - Rôle du pathologiste dans la prise en charge des tumeurs osseuses primitives malignes : ostéosarcomes et tumeurs de la famille Ewing après traitement néoadjuvant
Anne Gomez-Brouchet, Corinne Bouvier, Anne-Valérie Decouvelaere, Frédérique Larousserie, Sébastien Aubert, Xavier Leroy, Jean-Marc Guinebretière, Aurore Coulomb, Elisabeth Cassagnau, Anne de Muret, Virginie Audard, Béatrice Marie, Gonzague de Pinieux
Annales de Pathologie.2011; 31(6): 455. CrossRef - Potential transcriptional regulatory regions exist upstream of the human ezrin gene promoter in esophageal carcinoma cells
S. Gao, Y. Dai, M. Yin, J. Ye, G. Li, J. Yu
Acta Biochimica et Biophysica Sinica.2011; 43(6): 455. CrossRef - YY1 overexpression is associated with poor prognosis and metastasis-free survival in patients suffering osteosarcoma
Filomena de Nigris, Licciana Zanella, Francesco Cacciatore, Anna De Chiara, Flavio Fazioli, Gennaro Chiappetta, Gaetano Apice, Teresa Infante, Mario Monaco, Raffaele Rossiello, Gaetano De Rosa, Marco Alberghini, Claudio Napoli
BMC Cancer.2011;[Epub] CrossRef - 17β-Estradiol Enhances Breast Cancer Cell Motility and Invasion via Extra-Nuclear Activation of Actin-Binding Protein Ezrin
Shuhui Zheng, Jinghe Huang, Kewen Zhou, Chengxi Zhang, Qiuling Xiang, Zhi Tan, Tinghuai Wang, Xiaodong Fu, Jean-Marc Vanacker
PLoS ONE.2011; 6(7): e22439. CrossRef - Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas
Ana Carneiro, Pär-Ola Bendahl, Måns Åkerman, Henryk A Domanski, Anders Rydholm, Jacob Engellau, Mef Nilbert
Journal of Clinical Pathology.2011; 64(8): 689. CrossRef - Immunoexpression of Ezrin and CD44 in Patients With Osteosarcoma
Erica Boldrini, Stela Verzinhasse Peres, Sandra Morini, Beatriz de Camargo
Journal of Pediatric Hematology/Oncology.2010; 32(6): e213. CrossRef - Prognostic and predictive biomarkers of canine osteosarcoma
Gayathri Thevi Selvarajah, Jolle Kirpensteijn
The Veterinary Journal.2010; 185(1): 28. CrossRef
- Osteosarcoma-Specific Genes as a Diagnostic Tool and Clinical Predictor of Tumor Progression
- 11,206 View
- 78 Download
- 34 Crossref
- Prognosis of pN3 Stage Gastric Cancer
- Jung Ryun Ahn, Minkyu Jung, Chan Kim, Min Hee Hong, Hong Jae Chon, Hye Ryun Kim, Hei-Cheul Jeung, Woo Jin Hyung, Sung Sook Lee, Hyun Cheol Chung, Sung Hoon Noh, Sun Young Rha
- Cancer Res Treat. 2009;41(2):73-79. Published online June 30, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.2.73
-
Abstract
PDFPubReaderePub
Purpose The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features.
Materials and Methods Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer. They underwent both gastrectomy and lymphadenectomy with a curative aim. We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis.
Results Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3. Among these 260 patients, 78 patients were classified as the pN3/M1 stage. For all the patients, the median follow-up period was 19 months (range: 1~108 months) and the median overall survival time was 16.2 months (95% CI, 14.1~18.3%). The 5-year survival rate of the pN3/M0 group was significantly higher than that of the pN3/M1 group (12.6% vs. 2.6%, respectively, p<0.0001). The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients.
Conclusion The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group. An advanced T stage was a predictor for a poor prognosis for the pN3 patients. Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.
-
Citations
Citations to this article as recorded by- GSK461364A suppresses proliferation of gastric cancer cells and induces apoptosis
Dilara Ataseven, Şeyma Taştemur, Fatih Yulak, Sebahattin Karabulut, Mustafa Ergul
Toxicology in Vitro.2023; 90: 105610. CrossRef - HDAC4 promotes the growth and metastasis of gastric cancer via autophagic degradation of MEKK3
Wei-Jie Zang, Yi-Lin Hu, Chen-Yu Qian, Ying Feng, Jia-Zhou Liu, Jun-Ling Yang, Hua Huang, Yi-Zhun Zhu, Wan-Jiang Xue
British Journal of Cancer.2022; 127(2): 237. CrossRef - Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancer
Zhe Gong, Jieyun Zhang, Weijian Guo
Cancer Medicine.2020; 9(23): 9052. CrossRef - S100A10 Accelerates Aerobic Glycolysis and Malignant Growth by Activating mTOR-Signaling Pathway in Gastric Cancer
Yan Li, Xiao-Yu Li, Li-Xiang Li, Ru-Chen Zhou, Yinhe Sikong, Xiang Gu, Bi-Ying Jin, Bing Li, Yan-Qing Li, Xiu-Li Zuo
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef - Oncología personalizada: principales biomarcadores en el pronóstico y tratamiento de tumores sólidos
Marta Molina Romero, Emilio José Laserna Mendieta, Gema María Varo Sánchez, María Concepción Alonso-Cerezo, María Orera Clemente
Revista del Laboratorio Clínico.2019; 12(3): e1. CrossRef - Is it worthy of adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for distal gastric cancers with No. 6 lymph node metastasis?
J. Zhang, S. Zou, R. Luo, Z. Zhu, Z. Wang, H. Xu, B. Huang
Clinical and Translational Oncology.2019; 21(12): 1699. CrossRef - Reduced expression of Rap1GAP as a prognostic biomarker for primary gastric cancer patients
Jingjing Zhao, Cong Mai, Desheng Weng, Changlong Chen, Ziqi Zhou, Yuan Liu, Zhiwei Zhou, Peng Wang
Cancer Biomarkers.2018; 22(3): 375. CrossRef - Prognostic Discrepancy of the 6th and 7th UICC N Classification for Lymph Node Staging in Gastric Cancer Patients after Curative Resection
Sung Jin Oh, Byoung Jo Suh, Jong Kwon Park, Sung Don Oh, Hang Jong Yu
Case Reports in Oncology.2017; 10(1): 57. CrossRef - Gastric biomarkers: a global review
Nick Baniak, Jenna-Lynn Senger, Shahid Ahmed, S. C. Kanthan, Rani Kanthan
World Journal of Surgical Oncology.2016;[Epub] CrossRef - MiR 21‐5p as a predictor of recurrence in young gastric cancer patients
Soo‐Kyung Park, Young Soo Park, Ji Yong Ahn, Eun‐Ju Do, Dongho Kim, Jee Eun Kim, kyoungwon Jung, Jeong‐Sik Byeon, Byong Duk Ye, Dong Hoon Yang, Sang Hyoung Park, Sung Wook Hwang, Hwoon‐Yong Jung, Seung‐Jae Myung
Journal of Gastroenterology and Hepatology.2016; 31(8): 1429. CrossRef - Functional polymorphisms in apoptosis pathway genes and survival in patients with gastric cancer
Dongying Gu, Mulong Du, Cuiju Tang, Haiyan Chu, Zhi Xu, Xinyin Huo, Weida Gong, Yongfei Tang, Jianwei Zhou, Na Tong, Yong Xu, Zhengdong Zhang, Meilin Wang, Jinfei Chen
Environmental and Molecular Mutagenesis.2014; 55(5): 421. CrossRef - Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer
Bang Wool Eom, Jungnam Joo, Young-Woo Kim, Daniel Reim, Ji Yeon Park, Hong Man Yoon, Keun Won Ryu, Jong Yeul Lee, Myeong-Cherl Kook
Surgery.2014; 155(3): 408. CrossRef - Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer
Yonghui Wu, Heike Grabsch, Tatiana Ivanova, Iain Beehuat Tan, Jacinta Murray, Chia Huey Ooi, Alexander Ian Wright, Nicholas P West, Gordon G A Hutchins, Jeanie Wu, Minghui Lee, Julian Lee, Jun Hao Koo, Khay Guan Yeoh, Nicole van Grieken, Bauke Ylstra, Sun
Gut.2013; 62(8): 1100. CrossRef - Validity and Necessity of Sub-classification of N3 in the 7thUICC TNM Stage of Gastric Cancer
Fang-Xuan Li, Ru-Peng Zhang, Han Liang, Ji-Chuan Quan, Hui Liu, Hui Zhang
Asian Pacific Journal of Cancer Prevention.2013; 14(3): 2091. CrossRef - Is the New Seventh AJCC/UICC Staging System Appropriate for Patients with Gastric Cancer?
Hong Man Yoon, Keun Won Ryu, Byung Ho Nam, Soo Jeong Cho, Sook Ryun Park, Jong Yeul Lee, Jun Ho Lee, Myeong-Cherl Kook, Il Ju Choi, Young-Woo Kim
Journal of the American College of Surgeons.2012; 214(1): 88. CrossRef - Comparison of the 6th and 7th Editions of the UICC TNM Staging System for Gastric Cancer: Results of a Chinese Single-Institution Study of 1,503 Patients
Wei Wang, Xiao-wei Sun, Chao-feng Li, Lin Lv, Yuan-fang Li, Ying-bo Chen, Da-zhi Xu, Rajiv Kesari, Chun-yu Huang, Wei Li, You-qing Zhan, Zhi-wei Zhou
Annals of Surgical Oncology.2011; 18(4): 1060. CrossRef
- GSK461364A suppresses proliferation of gastric cancer cells and induces apoptosis
- 11,938 View
- 76 Download
- 16 Crossref
- Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea
- Min Hee Hong, Hyo Song Kim, Chan Kim, Jung Ryun Ahn, Hong Jae Chon, Sang-Joon Shin, Joong-Bae Ahn, Hyun Cheol Chung, Sun Young Rha
- Cancer Res Treat. 2009;41(2):67-72. Published online June 30, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.2.67
-
Abstract
PDFPubReaderePub
Purpose The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC).
Materials and Methods Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment.
Results Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%).
Conclusion Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study.
-
Citations
Citations to this article as recorded by- pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation
Ling Wang, Fangqing Cai, Yixuan Li, Xiaolan Lin, Yuting Wang, Weijie Liang, Caiyu Liu, Cunze Wang, Junshan Ruan
International Journal of Nanomedicine.2024; Volume 19: 9821. CrossRef - Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis
Amit Joshi, Ishan Patel, Pratiksha Kapse, Manmohan Singh
Kidney Cancer.2022; 6(1): 37. CrossRef - High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
Yun Beom Sang, Hannah Yang, Won Suk Lee, Seung Joon Lee, Seul-Gi Kim, Jaekyung Cheon, Beodeul Kang, Chang Woo Kim, Hong Jae Chon, Chan Kim
Cancers.2022; 14(23): 5985. CrossRef - Prognostic factors for overall survival in patients with clear cell metastatic renal cell carcinoma
Dongrul Shin, Chang Wook Jeong, Cheryn Song, Minyong Kang, Seong Il Seo, Jung Kwon Kim, Hakmin Lee, Jinsoo Chung, Sung-Hoo Hong, Eu Chang Hwang, Cheol Kwak, Jae Young Park
Medicine.2021; 100(31): e26826. CrossRef - Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population
Ahmed Badran, Mahmoud A. Elshenawy, Amgad Shahin, Ali Aljubran, Ahmed Alzahrani, Abdelmoneim Eldali, Shouki Bazarbashi
JCO Global Oncology.2020; (6): 19. CrossRef - Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
Motohide Uemura, Yoshihiko Tomita, Hideaki Miyake, Shingo Hatakeyama, Hiro‐omi Kanayama, Kazuyuki Numakura, Toshio Takagi, Tomoyuki Kato, Masatoshi Eto, Wataru Obara, Hirotsugu Uemura, Toni K. Choueiri, Robert J. Motzer, Yosuke Fujii, Yoichi Kamei, Yoshik
Cancer Science.2020; 111(3): 907. CrossRef - First-Line Axitinib Versus Sorafenib in Asian Patients with Metastatic Renal Cell Carcinoma: Exploratory Subgroup Analyses of Phase III Data
Xinan Sheng, Feng Bi, Xiubao Ren, Ying Cheng, Jinwan Wang, Brad Rosbrook, Ming Jiang, Jun Guo
Future Oncology.2019; 15(1): 53. CrossRef - The Roles of Common Variation and Somatic Mutation in Cancer Pharmacogenomics
Hiu Ting Chan, Yoon Ming Chin, Siew-Kee Low
Oncology and Therapy.2019; 7(1): 1. CrossRef - Risk of fatal adverse events in cancer patients treated with sunitinib
Bin Zhao, Hong Zhao, Jiaxin Zhao
Critical Reviews in Oncology/Hematology.2019; 137: 115. CrossRef - Temsirolimus in Asian Metastatic/Recurrent Non-clear Cell Renal Carcinoma
Jii Bum Lee, Hyung Soon Park, Sejung Park, Hyo Jin Lee, Kyung A Kwon, Young Jin Choi, Yu Jung Kim, Chung Mo Nam, Nam Hoon Cho, Beodeul Kang, Hyun Cheol Chung, Sun Young Rha
Cancer Research and Treatment.2019; 51(4): 1578. CrossRef - Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients
Claudia Arena, Giuseppe Troiano, Alfredo De Lillo, Nunzio F. Testa, Lorenzo Lo Muzio
BioMed Research International.2018; 2018: 1. CrossRef - Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma
Nahjatul Kursyiah Abd Ghafar, Adlinda Alip, Teng Aik Ong, Ning Yi Yap, Marniza Saad
Journal of Cancer Research and Therapeutics.2018; 14(6): 1303. CrossRef - Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
Xiaoyan Liu, Marta Fiocco, Jesse J. Swen, Henk-Jan Guchelaar
Acta Oncologica.2017; 56(4): 582. CrossRef - Oncogenic miR-100-5p is associated with cellular viability, migration and apoptosis in renal cell carcinoma
Peijie Chen, Canbin Lin, Jing Quan, Yulin Lai, Tao He, Liang Zhou, Xiang Pan, Xueling Wu, Yong Wang, Liangchao Ni, Shangqi Yang, Tao Wang, Yongqing Lai
Molecular Medicine Reports.2017; 16(4): 5023. CrossRef - miR‑660‑5p is associated with cell migration, invasion, proliferation and apoptosis in renal cell carcinoma
Tao He, Peijie Chen, Lu Jin, Jia Hu, Yifan Li, Liang Zhou, Shangqi Yang, Xiangming Mao, Yaoting Gui, Yun Chen, Yongqing Lai
Molecular Medicine Reports.2017;[Epub] CrossRef - Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma
Krisztián Nagyiványi, Barna Budai, Krisztina Bíró, Fruzsina Gyergyay, László Noszek, Zsófia Küronya, Hajnalka Németh, Péter Nagy, Lajos Géczi
Clinical Genitourinary Cancer.2016; 14(4): 314. CrossRef - BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen
Jung-woo Chae, Yi Ling Teo, Han Kiat Ho, Jaeyeon Lee, Hyun-moon Back, Hwi-yeol Yun, Mats O. Karlsson, Kwang-il Kwon, Alexandre Chan
Cancer Chemotherapy and Pharmacology.2016; 78(3): 623. CrossRef - Key predictive factors for efficacy of axitinib in first-line
metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a
randomized, double-blind phase II study
Yoshihiko Tomita, Satoshi Fukasawa, Mototsugu Oya, Hirotsugu Uemura, Nobuo Shinohara, Tomonori Habuchi, Brian I. Rini, Ying Chen, Angel H. Bair, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
Japanese Journal of Clinical Oncology.2016; 46(11): 1031. CrossRef - Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction
Siew-Kee Low, Koya Fukunaga, Atsushi Takahashi, Koichi Matsuda, Fumiya Hongo, Hiroyuki Nakanishi, Hiroshi Kitamura, Takamitsu Inoue, Yoichiro Kato, Yoshihiko Tomita, Satoshi Fukasawa, Tomoaki Tanaka, Kazuo Nishimura, Hirotsugu Uemura, Isao Hara, Masato Fu
PLOS ONE.2016; 11(2): e0148177. CrossRef - Sunitinib therapy for metastatic renal cell carcinoma: A urologist’s perspective
M Darrad, R Wilson
Journal of Clinical Urology.2016; 9(1): 32. CrossRef - Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
Rafael Corrêa Coelho, Tomás Reinert, Franz Campos, Fábio Affonso Peixoto, Carlos Augusto de Andrade, Thalita Castro, Daniel Herchenhorn
International braz j urol.2016; 42(4): 694. CrossRef - Tumor suppressor miR-149-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma
LU JIN, YIFAN LI, JIAJU LIU, SHANGQI YANG, YAOTING GUI, XIANGMING MAO, GUOHUI NIE, YONGQING LAI
Molecular Medicine Reports.2016; 13(6): 5386. CrossRef - Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore
Hui Shan Tan, Huihua Li, Yu Wen Hong, Chee-Keong Toh, Alvin Wong, Gilberto Lopes, Miah Hiang Tay, Alexandre Chan, Xin Yao, Tiffany Tang, Quan Sing Ng, Ravindran Kanesvaran, Noan Minh Chau, Min-Han Tan
Clinical Genitourinary Cancer.2015; 13(4): e285. CrossRef - Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial
Eduard Vrdoljak, Lajos Géczi, Jozef Mardiak, Tudor-Eliade Ciuleanu, Sophie Leyman, Ke Zhang, Peter Sajben, Laszlo Torday
Pathology & Oncology Research.2015; 21(3): 775. CrossRef - Axitinib plasma pharmacokinetics and ethnic differences
Ying Chen, Akiyuki Suzuki, Michael A. Tortorici, May Garrett, Robert R. LaBadie, Yoshiko Umeyama, Yazdi K. Pithavala
Investigational New Drugs.2015; 33(2): 521. CrossRef - Management of dose variability and side effects for individualized cancer pharmacotherapy with tyrosine kinase inhibitors
Tomohiro Terada, Satoshi Noda, Ken-ichi Inui
Pharmacology & Therapeutics.2015; 152: 125. CrossRef - RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
J.L. Lee, M.K. Kim, I. Park, J.-H. Ahn, D.H. Lee, H.M. Ryoo, C. Song, B. Hong, J.H. Hong, H. Ahn
Annals of Oncology.2015; 26(11): 2300. CrossRef - Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine‐refractory differentiated thyroid cancer
Naomi Kiyota, Martin Schlumberger, Kei Muro, Yuichi Ando, Shunji Takahashi, Yasukazu Kawai, Lori Wirth, Bruce Robinson, Steven Sherman, Takuya Suzuki, Katsuki Fujino, Anubha Gupta, Seiichi Hayato, Makoto Tahara
Cancer Science.2015; 106(12): 1714. CrossRef - Efficacy and Toxicity of Sunitinib in Metastatic Renal Cell Carcinoma Patients in Egypt
Wael Abdelgawad Edesa, Raafat Ragaey Abdelmalek
Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1971. CrossRef - Induction of apoptotic cell death by betulin in multidrug-resistant human renal carcinoma cells
NAM-HUI YIM, YOUNG PIL JUNG, AEYUNG KIM, TAESOO KIM, JIN YEUL MA
Oncology Reports.2015; 34(2): 1058. CrossRef - Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
Y Wang, T K Choueiri, J-L Lee, M-H Tan, S Y Rha, S A North, C K Kollmannsberger, D F McDermott, D Y C Heng
British Journal of Cancer.2014; 110(6): 1433. CrossRef - The Effect of ABCG2 Genotype on the Population Pharmacokinetics of Sunitinib in Patients With Renal Cell Carcinoma
Tomoyuki Mizuno, Masahide Fukudo, Tsuyoshi Fukuda, Tomohiro Terada, Min Dong, Tomomi Kamba, Toshinari Yamasaki, Osamu Ogawa, Toshiya Katsura, Ken-ichi Inui, Alexander A. Vinks, Kazuo Matsubara
Therapeutic Drug Monitoring.2014; 36(3): 310. CrossRef - Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
Ibrahim Yildiz, Fatma Sen, Leyla Kilic, Rumeysa Ciftci, Mert Basaran
Korean Journal of Urology.2014; 55(1): 74. CrossRef - Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries
Camillo Porta, Antonin Levy, Robert Hawkins, Daniel Castellano, Joaquim Bellmunt, Paul Nathan, Ray McDermott, John Wagstaff, Paul Donnellan, John McCaffrey, Francis Vekeman, Maureen P. Neary, Jose Diaz, Faisal Mehmud, Mei Sheng Duh
Cancer Medicine.2014; 3(6): 1517. CrossRef - Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
WILLIAM K. OH, DAVID McDERMOTT, CAMILLO PORTA, ANTONIN LEVY, REZA ELAIDI, FLORIAN SCOTTE, ROBERT HAWKINS, DANIEL CASTELLANO, JOAQUIM BELLMUNT, SUN YOUNG RHA, JONG-MU SUN, PAUL NATHAN, BRUCE A. FEINBERG, JEFFREY SCOTT, RAY McDERMOTT, JIN-HEE AHN, JOHN WAGS
International Journal of Oncology.2014; 44(1): 5. CrossRef - Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
R J Motzer, B Escudier, R Bukowski, B I Rini, T E Hutson, C H Barrios, X Lin, K Fly, E Matczak, M E Gore
British Journal of Cancer.2013; 108(12): 2470. CrossRef - Therapy management with sunitinib in patients with metastatic renal cell carcinoma: Key concepts and the impact of clinical biomarkers
Daniel Castellano, Alain Ravaud, Manuela Schmidinger, Guillermo De Velasco, Federico Vazquez
Cancer Treatment Reviews.2013; 39(3): 230. CrossRef - Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients
Hye Ryun Kim, Hyung Soon Park, Woo Sun Kwon, Ji Hyun Lee, Yusuke Tanigawara, Sun Min Lim, Hyo Song Kim, Sang Jun Shin, Jung Bae Ahn, Sun Young Rha
Cancer Chemotherapy and Pharmacology.2013; 72(4): 825. CrossRef - Validation of the MSKCC and Heng Risk Criteria Models for Predicting Survival in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib
Whi-An Kwon, In-Chang Cho, Ami Yu, Byung-Ho Nam, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
Annals of Surgical Oncology.2013; 20(13): 4397. CrossRef - Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma
Ki Hyang Kim, Sang Hyun Yoon, Hae-Jung Lee, Hyo Song Kim, Sang Joon Shin, Joong Bae Ahn, Sun Young Rha
Cancer Chemotherapy and Pharmacology.2013; 72(4): 853. CrossRef - Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain
Daniel Castellano, Mei Sheng Duh, Caroline Korves, Ellison Dial Suthoff, Maureen Neary, Luis Javier Hernández Pastor, Joaquim Bellmunt
Expert Opinion on Drug Safety.2013; 12(4): 455. CrossRef - Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib
Aiping Zhou, Wen Zhang, Chunxiao Chang, Xiaoyan Chen, Dafang Zhong, Qiong Qin, Donghua Lou, Haoyuan Jiang, Jinwan Wang
Cancer Chemotherapy and Pharmacology.2013; 72(5): 1043. CrossRef - Analysis of the Reasons for Dose Reduction or Discontinuation of Sunitinib in Korean Patients
노지혜, 이주연, 이혜숙, 김향숙, 강래영, 이용화
Journal of Korean Society of Health-System Pharmacists.2013; 30(3): 210. CrossRef - Effect of P-Glycoprotein and Breast Cancer Resistance Protein Inhibition on the Pharmacokinetics of Sunitinib in Rats
Sachiko Kunimatsu, Tomoyuki Mizuno, Masahide Fukudo, Toshiya Katsura
Drug Metabolism and Disposition.2013; 41(8): 1592. CrossRef - Famitinib in metastatic renal cell carcinoma: a single center study
Wen ZHANG, Ai-Ping ZHOU, Qiong QIN, Chun-Xiao CHANG, Hao-Yuan JIANG, Jian-Hui MA, Jin-Wan WANG
Chinese Medical Journal.2013; 126(22): 4277. CrossRef - Management of sunitinib adverse events in renal cell carcinoma patients: The Asian experience
Aiping ZHOU
Asia-Pacific Journal of Clinical Oncology.2012; 8(2): 132. CrossRef - Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients
Dok Hyun Yoon, Min-Hee Ryu, Baek-Yeol Ryoo, Moyeol Beck, Dae Ro Choi, Yoojin Cho, Jae-Lyun Lee, Heung-Moon Chang, Tae Won Kim, Yoon-Koo Kang
Investigational New Drugs.2012; 30(2): 819. CrossRef - Current Status of Targeted Therapy for Advanced Renal Cell Carcinoma
In-Chang Cho, Jinsoo Chung
Korean Journal of Urology.2012; 53(4): 217. CrossRef - Impact of Genetic Variation in Breast Cancer Resistance Protein (BCRP/ABCG2) on Sunitinib Pharmacokinetics
Tomoyuki Mizuno, Masahide Fukudo, Tomohiro Terada, Tomomi Kamba, Eijiro Nakamura, Osamu Ogawa, Ken-ichi Inui, Toshiya Katsura
Drug Metabolism and Pharmacokinetics.2012; 27(6): 631. CrossRef - Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey
I. Yildiz, F. Sen, M. Basaran, M. Ekenel, F. Agaoglu, E. Darendeliler, H. M. Tunc, F. Ozcan, S. Bavbek
Japanese Journal of Clinical Oncology.2011; 41(12): 1380. CrossRef - Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma
Yoshihiko Tomita, Hirotsugu Uemura, Hiroyuki Fujimoto, Hiro-omi Kanayama, Nobuo Shinohara, Hayakazu Nakazawa, Keiji Imai, Yoshiko Umeyama, Seiichiro Ozono, Seiji Naito, Hideyuki Akaza
European Journal of Cancer.2011; 47(17): 2592. CrossRef - Efficacy and Safety of Sunitinib on Metastatic Renal Cell Carcinoma: A Single-Institution Experience
Eugene Hwang, Hyo Jin Lee, Chong Koo Sul, Jae Sung Lim
Korean Journal of Urology.2010; 51(7): 450. CrossRef - Kidney Cancer Working Group Report
S. Naito, Y. Tomita, S. Y. Rha, H. Uemura, M. Oya, H. Z. Song, L. H. Zhong, M. I. B. A. Wahid
Japanese Journal of Clinical Oncology.2010; 40(Supplement): i51. CrossRef - Hematologic Toxicity in Patients Treated with Sunitinib for Advanced Thyroid Cancer
Anastasios Gkountouvas, Ifigeneia Kostoglou-Athanassiou, Eirini Veniou, Panagiotis Repousis, Nikolaos Ziras, Philippos Kaldrimidis
Thyroid.2010; 20(6): 597. CrossRef - The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction
C. Yoo, J. E. Kim, J.-L. Lee, J.-H. Ahn, D. H. Lee, J.-S. Lee, S. Na, C.-S. Kim, J. H. Hong, B. Hong, C. Song, H. Ahn
Japanese Journal of Clinical Oncology.2010; 40(10): 980. CrossRef - Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
Sang Hyun Yoon, Ki Hyang Kim, Junjeong Choi, Gun Min Kim, Joo Hoon Kim, Hyo Song Kim, Young Nyun Park, Sun Young Rha
Cancer Research and Treatment.2010; 42(3): 180. CrossRef - Comparative Analysis between Immunochemotherapy and Target Therapy for Metastatic Renal Cell Carcinoma: Overview of Treatment-Related Adverse Events and the Dropout Rate in Korea
Jee Han Lee, Sung-Goo Chang, Seung Hyun Jeon, Gyeong Eun Min, Koo Han Yoo
Korean Journal of Urology.2010; 51(6): 379. CrossRef
- pH-Responsive Block Copolymer Micelles of Temsirolimus: Preparation, Characterization and Antitumor Activity Evaluation
- 12,706 View
- 74 Download
- 57 Crossref
- Synthetic CDCA Derivatives-Induced Apoptosis of Stomach Cancer Cell Line SNU-1 Cells
- Bongkyung Moon, Min-Chan Kim, Joo-sung Park
- Cancer Res Treat. 2004;36(2):132-139. Published online April 30, 2004
- DOI: https://doi.org/10.4143/crt.2004.36.2.132
-
Abstract
PDFPubReaderePub
Purpose This study was conducted to explore whether CDCA derivatives induce apoptosis in a stomach cancer cell line, and to dissect the detailed mechanism underlying apoptosis.
Materials and Methods The human stomach cancer cell line, SNU-1, cells were treated with the synthetic CDCA derivatives, HS-1199 and HS-1200. DNA and mitochondrial stains were used to detect apoptotic cells by fluorescence imaging or flow cytometry. The caspase-3 activity was measured by Western blotting.
Results Both the HS-1199 and HS-1200 induced decreased viabilities of the SNU-1 cells, in time-dependent manners. The CDCA derivatives demonstrated various apoptosis hallmarks, such as mitochondrial changes (reduction of MMP, cytochrome c release, and Smac/ DIABLO translocation), activation of caspase-3 (resulting in the degradation of PARP and DFF45), DNA fragmentation and nuclear condensation.
Conclusion The CDCA derivatives, HS-1199 and HS-1200, both induced apoptosis of the SNU-1 gastric cancer cells in caspase- and mitochondria-dependent fashions. Many important issues relating to their therapeutic applications remain to be elucidated.
-
Citations
Citations to this article as recorded by- The anticancer activity of bile acids in drug discovery and development
Weijian Li, Lu Zou, Shuai Huang, Huijie Miao, Ke Liu, Yajun Geng, Yingbin Liu, Wenguang Wu
Frontiers in Pharmacology.2024;[Epub] CrossRef - The Higher Expression of CDCA2 Associated with Poor Prognosis in Glioma
Xin Jin, Zhen-qing Sun, Gui-liang Zhou, Guo-jun Li, Shi-feng Deng, Zhongjie Shi
Disease Markers.2022; 2022: 1. CrossRef - Mechanism of Bile Acid-Induced Programmed Cell Death and Drug Discovery against Cancer: A Review
Jung Yoon Jang, Eunok Im, Yung Hyun Choi, Nam Deuk Kim
International Journal of Molecular Sciences.2022; 23(13): 7184. CrossRef - Functional, Diagnostic and Therapeutic Aspects of Bile
Monjur Ahmed
Clinical and Experimental Gastroenterology.2022; Volume 15: 105. CrossRef - Mode of Actions of Bile Acids in Avoidance of Colorectal Cancer Development; and their Therapeutic Applications in Cancers - A Narrative Review
Kulvinder Kochar Kaur, Gautam Nand K. Allahbadia, Mandeep Singh
Journal of Pharmacy and Nutrition Sciences .2022; 12: 35. CrossRef - Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy
Jean-François Goossens, Christian Bailly
Pharmacology & Therapeutics.2019; 203: 107396. CrossRef
- The anticancer activity of bile acids in drug discovery and development
- 10,254 View
- 39 Download
- 6 Crossref
- Intrapleural Chemotherapy with Cisplatin and Cytarabine in the Management of Malignant Pleural Effusion
- Kee Won Kim, Suk Young Park, Myung Sook Kim, Seok Chan Kim, Eun Hee Lee, So Young Shin, Jong Ho Lee, Jong Bum Kweon, Kuhn Park
- Cancer Res Treat. 2004;36(1):68-71. Published online February 29, 2004
- DOI: https://doi.org/10.4143/crt.2004.36.1.68
-
Abstract
PDFPubReaderePub
Purpose The purpose of this study was to evaluate the efficacy of intrapleural chemotherapy (IPC) with cisplatin and cytarabine in the management of malignant pleural effusion (MPE) from non-small-cell lung cancer (NSCLC).
Materials and Methods A prospective analysis was carried out on 40 patients with pathologically proven MPE from NSCLC who had received IPC. A single dose of cisplatin 100 mg/m2 plus cytarabine 1200 mg/m2 in 250 ml normal saline was instilled into the pleural space via a chest tube and drained 4 hours later. Patients were evaluated for toxicities and responses at 1, 2, & 3 weeks and then at monthly intervals if possible. Systemic chemotherapy was administered, if the patient agreed to receive it, after achieving complete control (CC) of MPE.
Results The median duration of chest tube insertion for drainage was 7 (3~32) days. Among the assessable 37 patients, CC and partial control (PC) were 32 (86.5%) and 4 (10.8%) patients, respectively (overall response rate 97.3%). The median duration of response was 12 months (2~23) and there were only two relapses of IPC after achieving CC. Among the 35 patients who were assessable until they died, 28 patients (80.0%) maintained CC until the last follow-up. There was only one toxic death and the toxicities of IPC, versus the results obtained, were deemed acceptable.
Conclusion The procedures were tolerable to the patients and chemotherapy-induced complications were at an acceptable level. The outcome of this trial indicates that IPC has a superior and long lasting treatment response in the management of patients with MPE from NSCLC.
-
Citations
Citations to this article as recorded by- Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
Zihui Li, Jie Deng, Fei Yan, Li Liu, Yanling Ma, Jianhai Sun
Scientific Reports.2023;[Epub] CrossRef - Survival Benefits for Pulmonary Adenocarcinoma With Malignant Pleural Effusion After Thoracoscopic Surgical Treatment: A Real-World Study
Xin Li, Mingbiao Li, Jinshuang Lv, Jinghao Liu, Ming Dong, Chunqiu Xia, Honglin Zhao, Song Xu, Sen Wei, Zuoqing Song, Gang Chen, Hongyu Liu, Jun Chen
Frontiers in Oncology.2022;[Epub] CrossRef - Modified indwelling pleural catheter versus silver nitrate pleurodesis for the management of malignant pleural effusion
Mohammed F. Abdelghany, Khaled Essmat, Atef Farouk El-Karn, Sahar Farghly Youssif
The Egyptian Journal of Chest Diseases and Tuberculosis.2022; 71(2): 248. CrossRef - Chinese herbal injections versus intrapleural cisplatin for lung cancer patients with malignant pleural effusion: A Bayesian network meta-analysis of randomized controlled trials
Yi-Fang Xu, Yun-Ru Chen, Fan-Long Bu, Yu-Bei Huang, Yu-Xin Sun, Cheng-Yin Li, Jodi Sellick, Jian-Ping Liu, Dan-Mei Qin, Zhao-Lan Liu
Frontiers in Oncology.2022;[Epub] CrossRef - Making cold malignant pleural effusions hot: driving novel immunotherapies
Pranav Murthy, Chigozirim N. Ekeke, Kira L. Russell, Samuel C. Butler, Yue Wang, James D. Luketich, Adam C. Soloff, Rajeev Dhupar, Michael T. Lotze
OncoImmunology.2019; 8(4): e1554969. CrossRef - Efficacy and safety of intrapleural cisplatin versus silver nitrate in treatment of malignant pleural effusion
Mohammad K. El Badrawy, Raed El-Metwally Ali, Asem A. Hewidy, Mohamed A. El-Layeh, Fatma M. F. Akl, Abdelhadi Shebl
Egyptian Journal of Bronchology.2018; 12(1): 98. CrossRef - Biodegradable drug-eluting pellets provide steady and sustainable cisplatin release in the intrapleural cavity: In vivo and in vitro studies
Yin-Kai Chao, Yu-Wen Wen, Kuo-Sheng Liu, Yi-Chuan Wang, Chih-Wei Wang, Shih-Jung Liu
International Journal of Pharmaceutics.2015; 484(1-2): 38. CrossRef
- Efficacy of hyperthermic intrathoracic chemotherapy for initially diagnosed lung cancer with symptomatic malignant pleural effusion
- 9,058 View
- 58 Download
- 7 Crossref
- Expression of P53, Bcl-2, Bax, and P-glycoprotein in Relation to Chemotherapeutic Response in Patients with Advanced Non-Small-Cell Lung Cance
- Suk Young Park, Eun Hee Lee, Kee Won Kim, Chul Seung Kay, Seok Chan Kim, Ji Won Suhr, Kyung Shick Lee
- J Korean Cancer Assoc. 2001;33(2):158-162.
-
Abstract
PDF
- PURPOSE
To evaluate the relationship between the expressions of p53, bcl-2, bax, and p-glycoprotein and the chemotherapeutic response seen in patients with advanced NSCLC.
MATERIALS AND METHODS
Forty-four patients pathologically proven as NSCLC were reviewed. They had undergone at least two cycles of the same chemotherapeutic agents (cisplatin 60 mg/m2 day 1+ vinorelbine 25 mg/m2 day 1, 8, 21-day cycle) and the clinical response was evaluated by WHO criteria. The expressions of p53, bcl-2, bax, and p-glycoprotein were determined by immunohistochemistry.
RESULTS
Patients recorded as CR (2/44) and PR (20/44) were classified as the responder group (22/44) and stable (17/44) and progression (5/44) as the non-responder group (22/44). Positive expression of p53, bcl-2, bax, and p-glycoprotein were 84.1%, 65.9%, 88.6%, and 61.4% respectively. The expression score of p53 was significantly higher in the non-responder group than that seen in the responder group (8.59+/-1.89 vs 5.32+/-2.15, p<0.05). However, the expression scores of bcl-2, bax, and p-glycoprotein were not significantly correlated with the clinical response.
CONCLUSION
This study suggests that p53 gene mutation plays an important role in the clinical response to chemotherapy including cisplatin and vinorelbine. In future investigations, the correlation with the survival time will be studied.
- 3,278 View
- 30 Download
- N-nitrosomorpholine Directed Preneoplastic Reprogramming of Nuclear Metabolism of Rat Hepatocytes
- Min Chan Kim, Jin Sook Jeong, Yong Chun Choi, Ghap Joong Jung, Sang Soon Kim
- J Korean Cancer Assoc. 2000;32(6):1075-1083.
-
Abstract
PDF
- PURPOSE
An attempt was made to investigate N-nitrosomorpholine (NNM) induced carcinogenic processes in rat liver.
MATERIALS AND METHODS
Rats were fed with NNM (200 mg/l) for 7 weeks, after then stopped. Length of telomere and activity of telomerase were analyzed. Hepatocytes were isolated and grown on tissue culture. Heat shock was treated at 43oC, and patterns of cell death ere evaluted by fluorescent study. Nuclei and nucleoli were isolated for analysis of various signal molecules.
RESULTS
Shortening of telomere length presented in NNM treated liver, but induction of telomerase was not found. Ex vivo hepatocytes from 10~12th week showed increased heat shock resistance at 43oC. NNM-treated hepatocytes exhibited heat shock induced cell death (necrosis) after 7 hours, whereas the control showed necrosis after 3 hours. The signal molecules related to nucleolar growth revealed increased expression which included B23, C23, p38, Erk1/2 and p120. Partial degradation of B23 and Erk2 was noted in necrosis of NNM treated hepatocytes induced by heat shock.
CONCLUSION
The hepatocytes at the stage of 10~12th week in the stop experiment of NNM are situated in the tumour promotion. Those cells showed various metabolic alterations. We found that the increased growth related signals were accompanied with increased heat shock resistance, telomere shortening but no induction of telomerase.
- 2,396 View
- 13 Download
- Study of Ex Vivo Growth Characteristics of N-Nitrosomorpholine Treated Rat Hepatocytes
- Sung Sik Kang, Min Chan Kim, Jin Sook Jeong, Yong Chun Choi, Sang Soon Kim
- J Korean Cancer Assoc. 2000;32(5):972-980.
-
Abstract
PDF
- PURPOSE
The early carcinogenic effect of N-nitrosomorpholine (NNM) on acquisition of increased survival and growth was investigated using ex vivo culture of 5th to 10th week rat liver hepatocytes after NNM treatment.
MATERIALS AND METHODS
Rats were fed with NNM (200 mg/l). Hepatocytes were isolated by two step perfusion techniques and grown on tissue culture. These ex vivo hepatocytes were then subjected to analysis of growth related signal molecules resided in nucleoli.
RESULTS
One of the most characteristic differences of the NNM-treated liver from normal liver was genesis of megahepatocytes. These megahepatocytes survived approximately 2~3 times as long as normal hepatocytes in ex vivo conditions. There was also a significant increase in various nucleolar proteins, including Erk1/2, p38, hsp72 and nucleophosmin (B23).
CONCLUSION
At promotion stage of tumorigenesis induced by NNM, it was possible to isolate and characterize abnormal hepatocytes. These abnormal hepatocytes showed increased survival in in vitro (ex vivo) than normal hepatocytes, although they were not immortal.
- 2,487 View
- 13 Download
- Apoptosis Induction of Stomach Cancer Cell by TNF alpha and TGFbeta
- Min Seon Park, Wan Seop Kim, Kye Young Kim, Ji Yeon Seol, Kyu Chan Kimm, Byung Re Min, Myeong Jin Nam
- J Korean Cancer Assoc. 1999;31(2):209-218.
-
Abstract
PDF
- PURPOSE
Apoptosis is a physiological mechanism for deleting cells from the body for development and homeostasis. Exogenous cytokines such as tumor necrosis factor alpha (TNFalpha) and transforming growth factor beta (TGF beta) are known to modulate apoptosis, thus can provide a new therapeutic modality for various malignancies. We studied whether TNFalpha or TGFbeta can induce apoptosis or exert antiproliferative effect on human gastric cancer cell line (AGS) and which genes are involved in the cytokine-induced apoptotic pathway.
MATERIALS AND METHODS
To examine the effect of TNFalpha or TGF beta on AGS cell line (human gastric adenocarcimoma), we performed following tests; MTT test, trypan blue dye exclusion assay and colony forming efficiency. Total DNA was extracted from the TNFalpha-treated AGS cells and DNA ladder was detected as the hallmark of apoptosis, and flow cytometry analysis was performed for another apoptotic index. The effects of TNFalpha on c-myc expression was observed using RT-PCR.
RESULTS
TNFalpha suppressed AGS cell growth, in a time- and dose-dependent manner, but TGFbeta had no effect on AGS cell growth. Electrophoretic analysis of total cellular DNA revealed the pattern of internucleosomal DNA cleavage, which is specific for apoptosis and the effect was observed from 24 to 72 hrs after 50 ng/ml TNFalpha treatment. Time-dependent increse of apoptotic cells by TNFalpha was detected by flow cytometry analysis. Morphological changes such as cell to cell contacts and extension of cell processes were observed in TNFalpha-treated AGS cells. RT-PCR using c-myc primers showed thatthe mRNA levels were increased 6 hrs after TNFalpha treatment and persisted for 72 hrs.
CONCLUSION
It is suggested that TNFalpha, but not TGF beta, functions as an important inducer of apoptosis in AGS cell line, and c-myc may function as a critical endogenous activator of the pathway leading to cell death of AGS cells.
- 3,328 View
- 51 Download
- Linear Accelerator-Based Stereotactic Radiosurgery for Acoustic Neurinomas
- Hong Seok Jang, Sei Chul Yoon, Tae Suk Suh, Mi Ryeong Ryu, Yeon Shil Kim, Moon Chan Kim, Jun Ki Kang, Kyung Sub Shinn
- J Korean Cancer Assoc. 1997;29(6):992-999.
- 2,568 View
- 14 Download
- A Case of Cardiac Metastasis of Chondrosarcoma
- Seung Park Yoo, Bo Yun Chung, Ki Chan Kim, Yeul Hong Kim, Jeong Sik Park, Hyo Jin Lee
- J Korean Cancer Assoc. 1994;26(2):345-351.
-
Abstract
PDF
- Metastatic cardiac cancers are more prevalent than generally realized. So prompt recognition is mandatory if any cardiovascular manifestations develop in a patient with a malignant lesion elswhere in the body. Sixty-five year old male patient who had past history of resected chondrosarcoma on the 10th rib of left side presented as a local recurrence and dyspnea. Chest C-T findings demonstrated thrombose on right atrium and superior vena cava. Two-dimensional echocardiographic study showed mild pericardial effusion with a small mass attached to the visceral pericardium and a huge mass occupying nearly entire right atrial chamber with extension to superior vena cava. These findings are suggestive of cardiac metastasis of chon- drosarcoma.
- 2,784 View
- 17 Download
- Treatment of Advanced Gastric Cancer with Oral UFT and Leucovorin
- Seong Kyoon Cheong, Ki Chan Kim, Yeul Hong Kim, Sang Won Shin, Jun Suk Kim
- J Korean Cancer Assoc. 1994;26(3):369-377.
-
Abstract
PDF
- We conducted a phase II trial of oral administration of UFT and leucovorin in patients with advanced gastric adenocarcinoma. Sixteen patients entered on this study from September 1992 to November 1993. The treatment regiman consisted of oral administration of UFT (480 mg/m/day), and leucovorin (25 mg/ m(2)/day) for 21 consecutive days. The dosage of UFT was adjusted after each treatment and the treatment was repeated every 4 weeks. The total number of administered treatments in 16 patients was 55 and the median number was 4. Among 14 evaluable patients, 1 patient (7.2%) had a complete response and 3 patients (30%) achieved paritial response resulting in an overall response rate of 28.5%. The median duration of response was 15 weeks (4+- 48+). The median survival time for all 16 patients was 24 weeks (4+- 48+). Gastrointestinal toxicity was common and toxicity over grade 3 included diarrhea in 7 patients (43.8%), mucositis in 2 patients (12.5%) and anorexia, nausea and vomiting in 1 patient respectively. Grade 1 leukopenia was observed in 3 patients (18.8%). In conclusion, oral administration of UFT and leucovorin in patients with advanced gastric cancer who have poor general condition seems to be comparable to ther chemotherapy regi- mens in efficacy and toxicity.
- 2,306 View
- 17 Download
First
Prev
